Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

Background: Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). Several cohorts reported that people treated by tenofovir disoproxil fumarate and emtricitabine are less likely to develop SARS CoV-2 infection and related severe COVID-19. M...

Full description

Bibliographic Details
Main Authors: Jean-Jacques Parienti, Thierry Prazuck, Laure Peyro-Saint-Paul, Anna Fournier, Cécile Valentin, Sylvie Brucato, Renaud Verdon, Aymeric Sève, Mathilda Colin, Fabien Lesne, Jérome Guinard, Meriadeg Ar Gouilh, Julia Dina, Astrid Vabret, Laurent Hocqueloux
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:EClinicalMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S258953702100273X

Internet

http://www.sciencedirect.com/science/article/pii/S258953702100273X

Similar Items